N2B

Company Overview

Snapshot

Founded in January 2015, N2B operated with 1–10 employees. The company was incubated by Youdim Pharmaceuticals in January 2015, marking a key early development.

Business overview

N2B Ltd specializes in the development of an intranasal delivery formulation of the approved drug Rasagiline, specifically targeting the treatment of depression associated with Parkinson's disease (PD). The company aims for a rapid regulatory pathway for NDA submission through the U.S. FDA 505(b)(2) approach. Its preclinical research indicates that intranasal Rasagiline could offer an alternative to oral administration for PD treatment and a novel therapeutic approach for depression in PD patients. N2B operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals, mental health, degenerative diseases, neurology, and Parkinson's treatments.

Company Intelligence Q&A

What is N2B's primary focus?

N2B is focused on developing an intranasal delivery formulation of Rasagiline for the treatment of depression associated with Parkinson's disease.

When was N2B founded?

N2B was founded in January 2015.

What is N2B's regulatory strategy?

N2B is pursuing a quick regulatory pathway for NDA submission through the U.S. FDA 505(b)(2) approach.

What is the status of N2B's operations?

N2B ceased to operate in August 2017.

Which entity incubated N2B?

N2B was incubated by Youdim Pharmaceuticals in January 2015.